Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford University doctors and scientists are performing the second phase of clinical studies of an experimental Ebola vaccine regimen. The study is part of the EBOVAC2 project, a collaborative programme involving the University of Oxford, French Institute of Health and Medical Research (INSERM) as project coordinator, London School of Hygiene & Tropical Medicine, Le Centre Muraz, Inserm Transfert (IT) and the Janssen Pharmaceutical Companies of Johnson & Johnson.

What is unhealthy about public health? Vaccination, evidence and the politics of uncertainty

Journal article

Mezza M. and Vanderslott S., (2026), Humanities and Social Sciences Communications, 13

Accurately modeling RNase H-mediated antisense oligonucleotide efficacy

Journal article

Hill B. et al, (2026), Molecular Therapy Nucleic Acids, 37

Timing matters: Exon skipping therapy is most effective when initiated early in a mouse model of Duchenne muscular dystrophy

Journal article

Stenler S. et al, (2026), Molecular Therapy Nucleic Acids, 37, 103017 - 103017

ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.

Journal article

Ebrahimi N. et al, (2026), Vaccine, 88

Conference report: airway mucosal sampling and immune analysis.

Journal article

Rosenheim J. et al, (2026), Vaccine, 88

Emerging Therapies for Angelman Syndrome.

Journal article

Tychon C. et al, (2026), CNS Drugs

Load More